Overview
Blood leakage monitor maker's Q1 net sales rose yr/yr, company returned to profit
Company attributes growth to increased usage and broader adoption of installed systems
First Clamp System sale completed in UK clinic during Q1
Outlook
Company aims to increase end-customer usage in the U.S. and expand into new markets in 2026
Redsense plans to progress rollout of the Clamp and support broader adoption in 2026
Company expects stronger operational base and commercial approach to support continued growth
Result Drivers
INCREASED USAGE - Co said higher sales of disposables indicated increased usage of previously installed systems and strengthened underlying demand
REVISED PRICING STRUCTURE - Co said new U.S. pricing, with lower per-treatment consumable cost, supported broader adoption and contributed to higher usage
INVENTORY PRICING RECONCILIATION - Part of Q1 sales increase reflected a reconciliation of pricing on existing U.S. inventory ahead of the change
Company press release:
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 6.40 mln
Q1 EPS
SEK 0.07
Q1 Net Income
SEK 1.12 mln
Q1 EBIT
SEK 1.08 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .